Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
NetChoice Leads Tech’s Legal Battle Against State Regulation Tech trade association NetChoice has become the chief litigator for the industry. In the last few years the organization has filed 10...
AI in Healthcare Bills Awaiting Gov’s Action in CA California could soon establish new guardrails for the use of artificial intelligence in healthcare with a pair of bills awaiting action by Gov...
If an autonomous vehicle hits another car or a pedestrian, who’s to blame? The manufacturer or software developer? Other parties like computer programmers, satellite mapping companies, or even state...
Tech Lobby Zeroes In on AI Bill in CA Opponents of a first-of-its-kind bill ( SB 1047 ) in California aimed at regulating major developers of artificial intelligence outnumbered supporters of the measure...
CA Nears Restricting Private-Equity Healthcare Acquisitions The California Legislature passed a bill ( AB 3129 ) that, if signed by Gov. Gavin Newsom (D), would require the state attorney general’s...
A bill (SB 410) debated in the Michigan Senate last week would allow residents and state and local governments to sue drug manufacturers and sellers if their products cause injury. In 1995 the state passed the strongest drug immunity law in the nation, shielding drugmakers and sellers almost entirely from such suits. (BRIDGE MICHIGAN)
This year at least 24 states have enacted legislation dealing with health system consolidation and competition, according to the National Conference of State Legislatures. Among many other things the measures address the review and approval of health system mergers, reforms of health system contracting and certificate of need review. (NCSL)
California Gov. Gavin Newsom vetoed a bill (SB 90) that would have prohibited insurers from charging consumers more than $35 out of pocket for a 30-day supply of insulin. Earlier this year the governor announced the state would be partnering with the nonprofit pharmaceutical company Civica Rx to produce its own insulin, which it plans to sell for $30. (ASSOCIATED PRESS, STATE NET)
American taxpayers are overpaying for Medicare Advantage, or Medicare Part C—under which insurance companies are paid by the federal government to manage patient care—by at least $88 billion per year and possibly as much as $140 billion per year, according to a report published by Physicians for a National Health Program. “Various elements of MA, either by design or by consequence, result in a much higher level of government spending than is necessary to provide Medicare benefits, with much of this money going toward corporate profits,” the report states. (MEDICAL ECONOMICS)
—Compiled by SNCJ Managing Editor KOREY CLARK